Journal of the Korean Academy of Child and Adolescent Psychiatry

Korean Academy of Child and Adolescent Psychiatry (대한소아청소년정신의학회)
권호 표지
DOI QR코드

DOI QR Code

Demographic Characteristics, Medication Profile and Treatment Outcome of Patients with Very Early-Onset Schizophrenia in One Hospital

일병원에서 진단된 극조기발병조현병 환자의 인구학적 특성, 약물치료 양상 및 치료결과

  • Choi, SungKu (Division of Medical Services, National Center for Mental Health) ;
  • Cho, Hye-Kyung (Division of Medical Services, National Center for Mental Health) ;
  • Lee, Min-Koo (Department of Information and Statistics, Chungnam National University)
  • 최성구 (국립정신건강센터 의료부) ;
  • 조혜경 (국립정신건강센터 의료부) ;
  • 이민구 (충남대학교 정보통계학과)
  • Received : 2016.12.05
  • Accepted : 2017.02.04
  • Published : 2017.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: Very early-onset schizophrenia (VEOS) is a type of psychosis having a low frequency, insidious onset, and devastating clinical outcome. In this study, the demographic features, information on medication, clinical outcomes, and intellectual capability of patients diagnosed with VEOS in a hospital were analyzed to provide therapeutic strategies for this type of schizophrenia. Methods: Using the electronic medical records of the National Center for Mental Health, 69 patients with VEOS were identified based on the DSM-5 criteria of schizophrenia. The data were summarized and analyzed according to the demographic characteristics, medications used, intellectual strength measured by the full intelligence quotient (FIQ) score, and current clinical status measured by the Clinical Global Impression-Severity (CGI-S) and various combinations of these parameters. Results: The screened study group contained similar numbers of males and females. The younger the onset of psychosis, the lower the frequency. The study population included a significantly higher proportion of births in the winter season than that of the general population. The 3 most frequently used antipsychotic medications were risperidone and its derivatives, clozapine and olanzapine. Valproic acid and divalproex sodium were the most commonly added drugs for outcome augmentation. 53.5% of the study population had received benzodiazepines and/or hypnotics. The average FIQ of the study population was 69.4, which is quite low compared to previous Korean studies with similar populations. There was a weak negative correlation between FIQ and CGI-S, but it was not statistically significant. The average CGI-S score was 4.2, which meant that the patients were moderately ill. Conclusion: This study demonstrated that patients with VEOS showed more frequent intellectual deficits at baseline and poorer outcomes than the control group. Risperidone, clozapine, valproic acid and their combinations were the most preferred medications for the treatment of psychosis. Benzodiazepines were quite commonly added for various reasons.

Keywords

References

  1. Madaan V, Dvir Y, Wilson DR. Child and adolescent schizophrenia: pharmacological approaches. Expert Opin Pharmacother 2008;9:2053-2068. https://doi.org/10.1517/14656566.9.12.2053
  2. Rabinowitz J, Levine SZ, Hafner H. A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophr Res 2006;88:96-101. https://doi.org/10.1016/j.schres.2006.07.007
  3. Reichert A, Kreiker S, Mehler-Wex C, Warnke A. The psychopathological and psychosocial outcome of early-onset schizophrenia: preliminary data of a 13-year follow-up. Child Adolesc Psychiatry Ment Health 2008;2:6. https://doi.org/10.1186/1753-2000-2-6
  4. Diaz-Caneja CM, Pina-Camacho L, Rodriguez-Quiroga A, Fraguas D, Parellada M, Arango C. Predictors of outcome in early-onset psychosis: a systematic review. NPJ Schizophr 2015;1:14005. https://doi.org/10.1038/npjschz.2014.5
  5. Clemmensen L, Vernal DL, Steinhausen HC. A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry 2012;12:150. https://doi.org/10.1186/1471-244X-12-150
  6. Hollis C. Developmental precursors of child- and adolescent-onset schizophrenia and affective psychoses: diagnostic specificity and continuity with symptom dimensions. Br J Psychiatry 2003;182:37-44. https://doi.org/10.1192/bjp.182.1.37
  7. Werry JS, McClellan JM, Chard L. Childhood and adolescent schizophrenic, bipolar, and schizoaffective disorders: a clinical and outcome study. J Am Acad Child Adolesc Psychiatry 1991;30:457-465. https://doi.org/10.1097/00004583-199105000-00017
  8. Eggers C, Bunk D. The long-term course of childhood-onset schizophrenia: a 42-year followup. Schizophr Bull 1997;23:105-117. https://doi.org/10.1093/schbul/23.1.105
  9. Vourdas A, Pipe R, Corrigall R, Frangou S. Increased developmental deviance and premorbid dysfunction in early onset schizophrenia. Schizophr Res 2003;62:13-22. https://doi.org/10.1016/S0920-9964(02)00429-2
  10. Kumra S, Charles Schulz S. Editorial: research progress in early-onset schizophrenia. Schizophr Bull 2008;34:15-17.
  11. Pencer A, Addington J, Addington D. Outcome of a first episode of psychosis in adolescence: a 2-year follow-up. Psychiatry Res 2005;133:35-43. https://doi.org/10.1016/j.psychres.2004.10.004
  12. Baribeau DA, Anagnostou E. A comparison of neuroimaging findings in childhood onset schizophrenia and autism spectrum disorder: a review of the literature. Front Psychiatry 2013;4:175.
  13. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006;63:721-730. https://doi.org/10.1001/archpsyc.63.7.721
  14. Vyas NS, Gogtay N. Treatment of early onset schizophrenia: recent trends, challenges and future considerations. Front Psychiatry 2012;3:1-5.
  15. Guy W. Clinical global impressions. In: Guy W, editor. ECDEU assessment manual for psychopharmacology-revised. Rockville: National Institute of Mental Health;1976. p.218-222.
  16. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 2001;40(7 Suppl):4S-23S. https://doi.org/10.1097/00004583-200107001-00002
  17. Addington J, Heinssen RK, Robinson DG, Schooler NR, Marcy P, Brunette MF, et al. Duration of untreated psychosis in community treatment settings in the United States. Psychiatr Serv 2015;66:753-756. https://doi.org/10.1176/appi.ps.201400124
  18. Lin A, Wardenaar KJ, Pontillo M, De Crescenzo F, Mazzone L, Vicari S, et al. Is it still correct to differentiate between early and very early onset psychosis? Schizophr Res 2016;170:211-216. https://doi.org/10.1016/j.schres.2015.11.020
  19. Torrey EF, Torrey BB, Peterson MR. Seasonality of schizophrenic births in the United States. Arch Gen Psychiatry 1977;34:1065-1070. https://doi.org/10.1001/archpsyc.1977.01770210079007
  20. Davies G, Welham J, Chant D, Torrey EF, McGrath J. A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophr Bull 2003;29:587-593. https://doi.org/10.1093/oxfordjournals.schbul.a007030
  21. Watson CG, Kucala T, Tilleskjor C, Jacobs L. Schizophrenic birth seasonality in relation to the incidence of infectious diseases and temperature extremes. Arch Gen Psychiatry 1984;41:85-90. https://doi.org/10.1001/archpsyc.1984.01790120089011
  22. Bodnar LM, Simhan HN, Powers RW, Frank MP, Cooperstein E, Roberts JM. High prevalence of vitamin D insufficiency in black and white pregnant women residing in the Northern United States and their neonates. J Nutr 2007;137:447-452. https://doi.org/10.1093/jn/137.2.447
  23. Pai NB, Laidlaw M, Vella SC. Augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the 'real world'. Acta Psychiatr Scand 2012;126:40-46. https://doi.org/10.1111/j.1600-0447.2012.01854.x
  24. Tracy DK, Joyce DW, Sarkar SN, Mateos Fernandez MJ, Shergill SS. Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia. BMC Psychiatry 2015;15:174. https://doi.org/10.1186/s12888-015-0559-x
  25. Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006;57:1094-1101. https://doi.org/10.1176/ps.2006.57.8.1094
  26. Novick D, Bousono M, Suarez D, Olivares JM, Montejo AL, Haro JM, et al. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:972-982. https://doi.org/10.1016/j.pnpbp.2005.06.003
  27. Clark RE, Xie H, Brunette MF. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry 2004;65:151-155. https://doi.org/10.4088/JCP.v65n0202
  28. Wu CS, Lin YJ, Liu SK. Benzodiazepine use among patients with schizophrenia in Taiwan: a nationwide population-based survey. Psychiatr Serv 2011;62:908-914. https://doi.org/10.1176/ps.62.8.pss6208_0908
  29. Alexander J, Tharyan P, Adams C, John T, Mol C, Philip J. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. Br J Psychiatry 2004;185: 63-69. https://doi.org/10.1192/bjp.185.1.63
  30. TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 2003;327:708-713. https://doi.org/10.1136/bmj.327.7417.708
  31. Gillies D, Sampson S, Beck A, Rathbone J. Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev 201318;9:CD003079.
  32. Fontanella CA, Campo JV, Phillips GS, Hiance-Steelesmith DL, Sweeney HA, Tam K, et al. Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study. J Clin Psychiatry 2016;77:661-667.
  33. Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 2010;71:103-108. https://doi.org/10.4088/JCP.08m04818yel
  34. Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 2012;69:476-483. https://doi.org/10.1001/archgenpsychiatry.2011.1532
  35. Tiihonen J, Mittendorfer-Rutz E, Torniainen M, Alexanderson K, Tanskanen A. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 2016;173: 600-606. https://doi.org/10.1176/appi.ajp.2015.15050618
  36. Bahn GH, Cho AR, Baik HC, Kim KT, Yoon DJ. The clinical characteristics of late-adolescent onset schizophrenia in psychiatric inpatients. J Korean Soc Biol Ther Psychiatry 2001;7:1:93-101.
  37. Bahn GH, Noh BG, Yoon DJ, Kim YH, Yeum TH. Comparison of clinical characteristics between inpatients with early & late-onset schizophrenia. J Korean Soc Biol Ther Psychiatry 2002;8:242-253.
  38. Chung DS, Lim MH, Kim SK, Jung GM, Hwang JW, Kim BN, et al. Comparison of demographic, clinical, psychological characteristics between childhood and adolescent-onset schizophrenia. J Korean Acad Child Adolesc Psychiatry 2005;16:219-230.
  39. Rossler W, Salize HJ, van Os J, Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005;15:399-409. https://doi.org/10.1016/j.euroneuro.2005.04.009
  40. McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull 1996;22:305-326. https://doi.org/10.1093/schbul/22.2.305
  41. Bergh S, Hjorthoj C, Sorensen HJ, Fagerlund B, Austin S, Secher RG, et al. Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10 years after baseline: The OPUS study. Schizophr Res 2016;175:57-63. https://doi.org/10.1016/j.schres.2016.03.025
  42. Joa I, Johannessen JO, Auestad B, Friis S, McGlashan T, Melle I, et al. The key to reducing duration of untreated first psychosis: information campaigns. Schizophr Bull 2008;34:466-472.
  43. Cullberg J, Mattsson M, Levander S, Holmqvist R, Tomsmark L, Elingfors C, et al. Treatment costs and clinical outcome for first episode schizophrenia patients: a 3-year follow-up of the Swedish "Parachute Project" and two comparison groups. Acta Psychiatr Scand 2006;114:274-281. https://doi.org/10.1111/j.1600-0447.2006.00788.x
  44. Carrion RE, Cornblatt BA, Burton CZ, Tso IF, Auther AM, Adelsheim S, et al. Personalized prediction of psychosis: external validation of the NAPLS-2 psychosis risk calculator with the EDIPPP project. Am J Psychiatry 2016;173:989-996. https://doi.org/10.1176/appi.ajp.2016.15121565